



## ADANI WILMAR LIMITED

Registered Office: "Fortune House", Nr Navrangpura Railway Crossing, Navrangpura, Ahmedabad - 380 009. CIN : U15146GJ1999PLC035320  
Phone: 079-26455650; Fax: 079-26455621; Email: investor.relations@adanilwilmor.in  
Website: www.adanilwilmor.com

### Extract of Unaudited Consolidated Financial Results for the Quarter and Nine months ended December 31, 2021

Sr. No.	Particulars	Quarter ended December 31, 2021	Nine months ended December 31, 2021	Quarter ended December 31, 2020
		(Unaudited)	(Unaudited)	(Unaudited)
1	Revenue from Operations	14,378.66	39,253.18	10,229.49
2	Net Profit for the period before taxes and Share in Profit/(Loss) of Joint Ventures (before Exceptional and/or Extraordinary items)	306.29	760.48	171.33
3	Net Profit for the period before taxes and before Share in Profit/(Loss) of Joint Ventures (after Exceptional and/or Extraordinary items)	306.29	760.48	171.33
4	Net Profit for the period after taxes and before Share in Profit/(Loss) of Joint Ventures (after Exceptional and/or Extraordinary items)	220.52	555.12	110.02
5	Net Profit for the period after taxes and after Share in Profit/(Loss) of Joint Ventures (after Exceptional and/or Extraordinary items)	211.41	569.45	127.39
6	Total Comprehensive Income for the period (Comprising of Profit for the period (after tax) and other Comprehensive Income (after tax))	209.69	563.87	127.10
7	Paid-Up Equity Share Capital (Face Value of ₹1 Each)	114.29	114.29	114.29
8	Earnings Per Share (Face Value of ₹1 Each) Basic and Diluted (in ₹) (Not Annualised)	1.85	4.98	1.11

**Notes:**  
1. The aforesaid results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on February 14, 2022.  
2. The Statutory Auditors have carried out limited review of consolidated financial results of the Company for the quarter and nine months ended on December 31, 2021.  
3. Additional information on Standalone Financial Results is as follows:

Sr. No.	Particulars	Quarter ended December 31, 2021	Nine months ended December 31, 2021	Quarter ended December 31, 2020
		(Unaudited)	(Unaudited)	(Unaudited)
a	Revenue from Operations	13,763.47	38,087.75	10,229.49
b	Profit Before Tax	322.34	785.32	172.07
c	Profit After Tax	240.66	584.85	111.02

4. The above is an extract of the detailed format of the Standalone and Consolidated Financial Results for the quarter and nine months ended on December 31, 2021 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Standalone and Consolidated Financial Results for the quarter and nine months ended on December 31, 2021 are available on the Stock Exchange websites [www.bseindia.com](http://www.bseindia.com) / [www.nseindia.com](http://www.nseindia.com) and Company's website [www.adanilwilmor.com](http://www.adanilwilmor.com).

For and on behalf of the Board of Directors

Place: Ahmedabad  
Date: February 14, 2022

**Angshu Malik**  
Managing Director and Chief Executive Officer

**GUJARAT WATER SUPPLY & SEWERAGE BOARD, Gandhinagar**  
Executive Engineer, P.H.W. Div., Nakhtrana  
Tender Notice No. 14 & 5 (3<sup>rd</sup> Attempt) Year 2021-22  
Executive Engineer, Public Health Works Division, Nakhtrana Kutch through e-tendering system in Work  
Providing, Supplying, Laying, Joining and Jaming Various Dia 60 & PVC Pipeline, Construction and Designing of WTP and Storage at various Varnasda Complex villages, Pump house and compound wall at various headworks, Pumping Machinery for Varnasda Complex, RWSS Augmentation Scheme (Under Nal Se Jal Programme 2020-21 Varnasda Complex) T: Nakhtrana & Bhuj (31<sup>st</sup> Attempt)  
Estimated Cost Rs. 14,58,750.60 (Tender ID No. 506002)  
Providing, Supplying, Laying, Joining and Jaming Various Dia 60 & PVC Pipeline, Construction Storage at various village, Pump house and compound wall at various Head works, Pumping Machinery and 6 year O&M Work For Suttari RWSS Augmentation Scheme (Under Nal Se Jal Programme 2021-22) T: Abdasa Kutch  
Estimated Cost Rs. 6,30,48,261.20 (Tender ID No. 506003)  
Tender can be downloaded after 08.11.2022 Last Date of online Submission is till 01.12.2022 at 18:00 Hours. Further details are available on the Website <http://www.geebn.org>  
Handing over of drinking water in rural areas, it is requested to, contact the helpline no. 1916/1900 200 1400 of Gujarat Water Supply & Sewerage Board, Gandhinagar.  
DD/KUTCH/1031/2022

	4,289.20	4,455.37	5,260.21	11,375.72	9,483.19	14,534.54
2	Net Profit/(Loss) for the period (before Tax and Exceptional items)	(9.98)	16.34	159.83	21.19	(181.19)
3	Net Profit/(Loss) for the period (Before Tax and after Exceptional items)	(9.98)	16.34	159.83	21.19	(181.19)
4	Net Profit/(Loss) for the period (after Tax and Exceptional items)	(5.12)	7.21	155.36	17.11	(187.01)
5	Total Comprehensive Income for the period (Profit/(Loss) for the period (after Tax) and other Comprehensive Income (after Tax)	(5.12)	7.21	155.36	17.11	(187.01)
6	Paid-up Equity share capital (face value) of Rs. 10-each share	950.00	950.00	950.00	950.00	950.00
7	Reserves (excluding Revaluation Reserve as shown in the Balance Sheet of previous year)	-	-	-	-	1,953.38
8	Earnings Per Share (before and after extraordinary items) (of Rs. 10/- each) Basic and Diluted	(0.05)	0.08	1.64	0.18	(1.97)

**Notes:**  
1. The above result is an extract of the details unaudited Financial Result for the Quarter and Nine Months ended 31st December, 2021 filed with the stock exchange under regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015. The full financial result for the Quarter and Nine Months ended on 31<sup>st</sup> December, 2021 are available on the website of the stock exchange i.e. [www.bseindia.com](http://www.bseindia.com) and website of the company i.e. [www.shreebhavyafabrics.com](http://www.shreebhavyafabrics.com)

For: **SHREE BHAVYA FABRICS LIMITED**  
Purushottam R. AGARWAL  
Managing Director  
(DIN: 08396868)

Place: Ahmedabad  
Date: 14.02.2022

## ATUL AUTO LIMITED

Reg. Office: Survey No. 86, Plot No. 1 to 4, 8-B, National Highway, Near Microwave Tower, Shapur (Veraval).  
Dist. Rajkot, Gujarat 360 024 CIN L54100GJ1986PLC019999 | Website: [www.atulauto.com](http://www.atulauto.com) | E-Mail: [info@atulauto.com](mailto:info@atulauto.com)

### Extract of Unaudited Standalone and Consolidated Financial Results for the Quarter and Nine Months ended on December 31, 2021

Sr. No.	Particulars	STANDALONE		CONSOLIDATED	
		Quarter Ended	Nine Months Ended	Quarter Ended	Nine Months Ended
		31.12.2021 (Unaudited)	31.12.2021 (Unaudited)	31.12.2021 (Unaudited)	31.12.2021 (Unaudited)
1	Total Income from Operation (Net)	9,377	10,171	20,796	10,284
2	Net Profit/(Loss) for the period (before Tax, Exceptional and/or Extra ordinary Items)	(1,134)	137	(2,549)	131
3	Net Profit/(Loss) for the period before Tax (after Exceptional and/or Extra ordinary Items)	(1,134)	137	(2,549)	131
4	Net Profit/(Loss) for the period after Tax (after Exceptional and/or Extra ordinary Items)	(852)	106	(1,920)	100
5	Total Comprehensive Income for the period (Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after tax))	(846)	99	(1,910)	118
6	Paid up Equity Share Capital	1,097	1,097	1,097	1,097
7	Earning Per Share (Basic and Diluted but not annualised) (Face value of Rs. 5/-)	(3.88)	0.47	(8.75)	0.57

**Notes:**  
The above is an extract of the detailed format of Quarterly Financial Results (Standalone and Consolidated) filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of financial results for the said Quarter and Nine Months end are available on Stock Exchanges Websites: [www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com). The same is also available on the website of the Company: [www.atulauto.com](http://www.atulauto.com)

Date: February 12, 2022  
Place: Shapur (Dist. Rajkot)



For and on behalf of Board of Directors of Atul Auto Limited  
**Jayantibhai J Chandra**  
Chairman & Managing Director  
(DIN : 00057722)

## Living with Covid 19



**Dr Shashank R Joshi**  
MD, DM, FICP, FICP, FACP  
Consultant Endocrinologist,  
Mumbai  
Member, Maharashtra  
COVID-19 Task force  
Padma Shri Awardee

SARS-CoV-2 to make significant evolutionary leaps where it may become a manageable condition in most and protecting the most vulnerable likely to deteriorate. We need to live our lives with Covid 19 with care, caution and precautions without fear and panic.

The novel coronavirus disease of 2019 is associated with significant morbidity and mortality. Our current focus is to save every life from covid 19. Most lives are lost in elderly or unvaccinated population or those who have underlying immunocompromised states or co morbid disorders like hypertension, diabetes, heart diseases or kidney or liver issues. The impact of thrombotic complications has been increasingly recognized as an important component of this disease associated with higher risk of death. To add to the burden of thromboembolism, winters are often accompanied with an unusually high occurrence of heart

attacks or strokes. Deaths from heart disease, including sudden deaths, tend to increase rapidly at the onset of winters. The risk of having a heart attack during the winter months is twice as high as during the summers. So, people with cardiometabolic conditions must take utmost care to prevent covid 19 or treat aggressively.

The quest for effective drugs to treat COVID-19 and vaccines to prevent complications has been a priority ever since the outbreak of the disease. Up to now, COVID treatment choices have been inferred from the experience with other coronaviruses or viral infection outbreaks. The options currently being used clinically are categorically divided as antivirals, immunomodulators and other drugs. However, it has been observed that the use of such drugs has shown both, limited efficacy & specificity against SAR-CoV-2 but evidence continues to be generated. Many of these medicines were repurposed and are still under investigation.

Flu and influenzas pandemics have ravaged the world since 1918 till date. Covid 19 had also seen waves and strains evolve which has seen it evolve from a life-threatening pneumonia like disease from the Wuhan strain till the current less severe Omicron strain which is flu like syndrome in most people now. Omicron related tsunami like wave is less severe but highly contagious. The manifestations of Omicron are essentially an upper airway disease which is "nose" and "throat" covid. They are fever, nasal congestion/stuffy or blocked nose, sore throat with pain, cough, headache, bodyache, tiredness (fatigue), myalgia (muscle pain) and many others. The lung covid which was seen in the Delta strain can still rarely exist often may have loss of smell and taste should never be missed. Monitoring temperature and oxygen saturation will always be the key in the first week particularly. Symptomatic treatment is the key with antipyretics, anti-inflammatory, antihistamines and simple immunity stimulating micronutrients. So current mild disease can be managed by symptomatic treatment solutions and red flagging the vulnerable groups. Simple medicines like low dose aspirin, statins or anticoagulants save lives in the high risk cardiometabolic co morbidities like diabetes and heart diseases.

## Need of the Hour : Boost Immunity



**Rohit Shelatkar**  
B Pharmacy, MSc. Pharmacology,  
Sr. Vice President, Director,  
Vitabiotics Ltd. UK

Heads the international business team along with his participation in the Product Formulations and Regulatory Affairs.

For those who had hoped that 2021 would be the year that put the pandemic in the past tense, it was a harsh reminder that it is still very much present. Rather than laying plans to return to the 'normal' life we knew before the pandemic, 2022 is the year the world must come to terms with the fact that SARS-CoV-2 is here to stay.

The emergence of the Omicron variant last November highlighted the ongoing challenges of life with SARS-CoV-2. The transmission rate increases with each new emerging variant & hence vaccine is only partially effective method of

anti-inflammatory agents and antivirals might be the optimal therapy for the disease. The emergence of affordable and powerful oral anti-COVID-19 drugs and the increased uptake of vaccination will bring hope for the end of the COVID-19 pandemic.

It takes years to develop antiviral drugs & looking at repurposing easily accessible which treat COVID symptoms. The need of the hour is to look at therapies that can be taken at home in tablet form to reduce hospital load. Knowledge & detailed science behind use of aspirin & promethazine in treating flu like symptoms backed by clinical evidence is sufficiently available.

Micronutrient have potential roles in interfering with virus at the entry site, and inhibiting activities of replication cycle of severe acute respiratory syndrome coronavirus Micro-nutrient also have immunomodulating, anti-inflammatory, antioxidant, and antiviral properties. Therefore, micronutrients are consequently a promising alternative nutritional approach to combat COVID-19.

In COVID, vitamin C up to 1500 mg provides optimum in COVID-19. Vitamin B3 not only helps to build and maintain a healthy immune system but it could potentially prevent or reduce COVID-19 symptoms or treat SARS-CoV-2 infection. Zinc has immunomodulatory, antiviral & anti-inflammatory responses and supplementing 15-30 mg Zinc per day in COVID infected is effective. Selenium and Iodine has beneficial effects on immunity, with a dose more than 100 µg per day.

The COVID-19 pandemic is still severe, and most of the drugs currently for COVID-19 are not designed specifically against SARS-CoV-2. The combination of Aspirin, Promethazine and micronutrients inhibits viral proliferation in early stage of COVID-19 thus preventing subsequent severe complications. Clinical evidence suggests that Aspirin, promethazine and micronutrients can shorten the recovery time of COVID-19 symptoms.

Need of the hour with omicron variant is to boost immunity of those vaccinated & unvaccinated as emerging variants tend to

